Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study to Assess the Steady-State Trough Serum Concentration, Safety, and Immunogenicity of Abatacept (BMS-188667) Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis Who Are Receiving Disease Modifying Ant-Rheumatic Drugs (DMARDs)
Brief Summary: The purpose of this study is to study serum levels of Abatacept after subcutaneous dosing in subjects with RA.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: methotrexate, Drug: rituximab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: methotrexate, Drug: rituximab, Drug: corticosteroids | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: methotrexate, Drug: rituximab, Drug: corticosteroids | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: methotrexate, Drug: rituximab | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: methotrexate, Drug: rituximab, Drug: corticosteroids | Arm Label: 6; Type: EXPERIMENTAL; Interventions: Drug: methotrexate, Drug: rituximab, Drug: corticosteroids | Arm Label: 7; Type: PLACEBO_COMPARATOR; Interventions: Drug: methotrexate, Drug: placebo | Arm Label: 8; Type: PLACEBO_COMPARATOR; Interventions: Drug: methotrexate, Drug: corticosteroids, Drug: placebo | Arm Label: 9; Type: PLACEBO_COMPARATOR; Interventions: Drug: methotrexate, Drug: corticosteroids, Drug: placebo | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): 1, 2, 3, 4, 5, 6, 7, 8, 9 | Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): 1, 2, 3, 4, 5, 6 | Intervention Type: DRUG; Name: corticosteroids; Assigned to Arm(s): 2, 3, 5, 6, 8, 9 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 7, 8, 9
B: Arm Label: Group 1 (weight < 60 kg); Type: PLACEBO_COMPARATOR; Interventions: Drug: Abatacept or Placebo (both as IV & SC Solution) | Arm Label: Group 2 (weight < 60 kg); Type: PLACEBO_COMPARATOR; Interventions: Drug: Abatacept or Placebo (both as IV & SC Solution) | Arm Label: Group 3 (weight 60-100 kg); Type: PLACEBO_COMPARATOR; Interventions: Drug: Abatacept or Placebo (both as IV & SC solution) | Arm Label: Group 4 (weight > 100 kg); Type: PLACEBO_COMPARATOR; Interventions: Drug: Abatacept or Placebo (both as IV & SC solution) | Arm Label: Group 5 (weight > 100 kg); Type: PLACEBO_COMPARATOR; Interventions: Drug: Abatacept or Placebo (both as IV & SC solution) | Arm Label: Abatacept; Type: EXPERIMENTAL; Interventions: Drug: Abatacept | Intervention Type: DRUG; Name: Abatacept or Placebo (both as IV & SC Solution); Assigned to Arm(s): Group 1 (weight < 60 kg) | Intervention Type: DRUG; Name: Abatacept or Placebo (both as IV & SC Solution); Assigned to Arm(s): Group 2 (weight < 60 kg) | Intervention Type: DRUG; Name: Abatacept or Placebo (both as IV & SC solution); Assigned to Arm(s): Group 3 (weight 60-100 kg) | Intervention Type: DRUG; Name: Abatacept or Placebo (both as IV & SC solution); Assigned to Arm(s): Group 4 (weight > 100 kg) | Intervention Type: DRUG; Name: Abatacept or Placebo (both as IV & SC solution); Assigned to Arm(s): Group 5 (weight > 100 kg) | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept
C: Intervention Type: DRUG; Name: Adalimumab 40 mg sc every other week; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A

Answer: B